End-of-day quote
Other stock markets
|
||
- USD | - |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Intellectual Property Licensing
64.9
%
| 0 | 21.4 % | 0 | 64.9 % | +169.06% |
Business-to-business Product
19.5
%
| 0 | 44.4 % | 0 | 19.5 % | -61.07% |
Research & Development
15.6
%
| 0 | 21.5 % | 0 | 15.6 % | -35.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -11.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Vanessa Carle
LAW | General Counsel | - | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
John Docherty
PSD | President | 53 | 15-04-14 |
Director/Board Member | 76 | 15-09-15 | |
Catherine Turkel
BRD | Director/Board Member | 63 | 22-09-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,885,673 | 11,240,368 ( 87.23 %) | 0 | 87.23 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.77% | 364B | |
+20.54% | 326B | |
+5.53% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+11.03% | 167B | |
+0.05% | 161B |
- Stock Market
- Equities
- LEXX Stock
- Stock
- Company Lexaria Corp